CBS 2019
CBSMD教育中心
中 文

Acute Coronary Syndrom

Abstract

Recommended Article

Treating Multivessel Coronary Artery Disease in ST-Segment Elevation Myocardial Infarction: Why, How, and When? TACIT (High Sensitivity Troponin T Rules Out Acute Cardiac Insufficiency Trial): An Observational Study to Identify Acute Heart Failure Patients at Low Risk for Rehospitalization or Mortality Symptom-Onset-To-Balloon Time, ST-Segment Resolution and In-Hospital Mortality in Patients With ST-Segment Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention in China: From China Acute Myocardial Infarction Registry Management of Myocardial Revascularization Failure: An Expert Consensus Document of the EAPCI Relation between door-to-balloon times and mortality after primary percutaneous coronary intervention over time: a retrospective study Acute Noncardiac Organ Failure in Acute Myocardial Infarction With Cardiogenic Shock Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction

Editorial2019 Apr 22;12(8):731-733.

JOURNAL:JACC Cardiovasc Interv. Article Link

Treating Multivessel Coronary Artery Disease in ST-Segment Elevation Myocardial Infarction: Why, How, and When?

Berry C, Collison D, Mangion K. Keywords: ST-segment elevation myocardial infarction; fractional flow reserve; multivessel disease; percutaneous coronary intervention; remodeling

LINK

Please click on "Article Link" to get further access to this Editorial.